Endocrine Abstracts

Objective: After Cushing Syndrome (CS) is cured, up to 70% of patients develop chronic adrenal insufficiency (AI) and hypothalamus-pituitary-adrenal (HPA) axis dysfunction. A long-term treatment with glucocorticoids (GC) is mandatory to overcome AI. However, this treatment implies non-desired complications. Fibroblast growth factor (FGF21), a key regulator of metabolism, has a bidirectional relationship with GC that bypasses the negative feedback of the HPA axis. In this study...

Background: Acinic cell carcinoma of the parotid gland is a rare cancer, and metastatic (M1) disease is uncommon, occurring in around 10% of cases, with ectopic paraneoplastic Cushing being described in only few cases.Clinical case: A 58-year-old woman, with a history of dedifferentiated parotid acinar cell carcinoma, underwent surgery and adjuvant radiotherapy in 2005. In February 2019 the disease recurred with pulmonary, bone and lymph node metastases....

Introduction: Clinical observational studies have reported the persistence of a high cardiovascular risk in patients with cured Cushing’s syndrome (CCS) compared with controls of the same age, gender and BMI. It is still at debated whether this is due to the persistence of comorbidities, hormone deficiencies or chronic changes induced by hypercortisolism. The aim of this translational approach was to investigate the interplay in CCS of the cardiovascular disease in vivo a...

Background: Long-term studies evaluating mortality in patients with non-functioning (NF) pituitary tumors (PitNets) are limited, although standardized mortality ratios (SMR) in these patients are reported to be higher than that of general population. There is also no agreement on predictive factors associated to the increased mortality apart from age at diagnosis and glucocorticoid substitution therapy dose.Objective: To assess long-term mortality and as...

Objectives: Most transgender persons (0.3-0.5% of total population) are under gender-affirming hormone therapy (GAHT). Several studies have reported an increased morbimortality due to cardiovascular events (CVE), infectious disease and suicide. However, these studies were made on small populations and short follow up. We evaluated the changes on anthropometric variables, risk factors for cardiovascular diseases (CVD) and CVE at 5 and 10 years of follow up in a transgender popu...

Introduction and rationale: Cushing’s syndrome (CS) is a rare disease with hypercortisolism caused either by ACTH excess from a pituitary or non-pituitary tumor or by an ACTH-independent primary adrenal overproduction of cortisol. It is associated with significant comorbidities potentially lethal: hypertension, diabetes, coagulopathy, cardiovascular disease, infections, and osteoporotic fractures. It is usually managed by surgery and/or medical treatment with steroidogene...

Purpose: To evaluate the prevalence of autonomous cortisol secretion (ACS) in patients with primary aldosteronism (PA) and its implications on cardiometabolic and surgical outcomes.Methods: A retrospective multicenter study of PA patients who underwent 1mg-dexamethasone suppression test (DST) in follow-up in 21 Spanish tertiary hospitals. ACS was defined as a cortisol post-DST >1.8μg/dL (confirmed ACS if >5μg/dL and possible ACS if between 1.8-...

We previously described a short version of the acute octreotide test (sAOT) for predicting somatostatin receptor ligands (SRLs) response in patients with acromegaly1. In the present work, we prospectively reassess the sAOT ability to identify SRLs response in patients from the ACROFAST study using the current GH standards and control criteria and we also correlate sAOT values with E-cadherin tumor expression. Methods: Patients from the ACROFAS...